

Jubilant, Aavis launch HCQ sulfate tablets in US

09 November 2020 | News

Hydroxychloroquine Sulfate Tablets are indicated for the treatment of Malaria, Lupus Erythematosus and Rheumatoid Arthritis



Jubilant Pharma Ltd. and US-based Aavis Pharmaceuticals Inc. has recently announced the launch of Hydroxychloroquine (HCQ) Sulfate tablets, 200 mg, a therapeutic equivalent version of Plaquenil (hydroxychloroquine sulfate) 200 mg in the US market. The product will be distributed by Jubilant Cadista, a unit of Jubilant Pharma Ltd.

Hydroxychloroquine Sulfate Tablets are indicated for the treatment of Malaria, Lupus Erythematosus and Rheumatoid Arthritis. "We are pleased to announce the commercial launch of Hydroxychloroquine Sulfate tablets in the US through our marketing partner," stated Ashok Barot, Chairman, Aavis Pharmaceuticals. "Our team is doing their best to fulfil the current surge in demand. We'll continue our efforts to be a significant and reliable supplier of this product," stated Swapnil Shah, Managing Director, Senores Pharmaceuticals, R&D partner and an affiliate of Aavis Pharmaceuticals.

"We are excited about this launch," stated Pramod Yadav, CEO, Jubilant Pharma Limited. "We are pleased to partner with Aavis to create access for the growing demand for this product and expand our basket of offerings in the US market," he added.